Why the study?
Do circulating Dipeptidyl peptidase 3 (cDPP3) plasma levels predict cardiogenic shock and mortality in patients with acute coronary syndromes?
Do circulating Dipeptidyl peptidase 3 (cDPP3) plasma levels predict cardiogenic shock and mortality in patients with acute coronary syndromes?
Answers are grounded in this paper and cite their sources.
Circulating DPP3 is a novel prognostic biomarker that improves early risk assessment for cardiogenic shock and mortality in patients with acute coronary syndromes.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Wenzl et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: